



## **EVITRADE Health Systems Applies for New Ticker in the United States for OTC Markets OTCQB® Venture Market Quotation**

VANCOUVER, BC, Thursday May 31, 2018 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: AXHLF) (the “Company”) announces that it has made a voluntary ticker symbol change application with FINRA for the Company’s quotation on the OTC Markets OTCQB® Venture Market. The symbol is expected to better reflect the corporate name and its new image as it continues to focus on Technology, Healthcare and Life Sciences.

“Although the Company has its headquarters in Canada, we have always considered the international markets key to our success and overall presence on the world stage. Changing the symbol for our US presence will enable the Company to continue to be relevant to its US and international shareholders” said Mr. CK Cheung, CEO of EVITRADE.

In an earlier release, the Company announced that it has signed a Letter of Intent to acquire the technology of Cantech Molecular Research Inc. (“Cantech”). The soon - to - be acquired Cantech and / or Cantech Intellectual Property (“IP”) specializes in systems for the manufacture of highly advanced plants grown through selective breeding (also known as cultivars) and the production of quality pharmaceutical products for use in agriculture and medicine.

Management continues to strive to seek optimal business and commercialization strategies for the Company such as the LOI with Cantech and with the recent continuing engagement of Haywood Securities.

Contact: Mr. CK. Cheung, CEO EVITRADE Health Systems Corporation

EVITRADE Health Systems Corporation  
(formerly Auxellence Health Corporation)

Email [info@evahealthsystems.com](mailto:info@evahealthsystems.com)

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets: <http://www.otcm Markets.com/stock/AXHLF/news>

### **About EVITRADE Health (CSE: EVA, OTCQB: AXHLF)**

*EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to develop “digital healthcare” technologies and services for resolving common health problems. The current markets are weight-loss, high blood pressure, high blood glucose and heart arrhythmia.*

### **Disclaimers – Forward Looking Statements**

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on [www.sedar.com](http://www.sedar.com), <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>,



**EViTRADE  
Health  
Systems  
Corporation**

and <http://www.otcmarkets.com/stock/AXHLF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.